方達控股(01521.HK)擬420萬加幣向收購加拿大BRI股權
格隆匯12月16日丨方達控股(01521.HK)發佈公告,有關集團收購於加拿大温哥華的BRI Biopharmaceutical Research, Inc.(“BRI”)。2019年12月13日,公司透過Frontage Laboratories, Inc.擁有的間接全資加拿大附屬公司11736655 CANADA LTD.與J&J Corporate Services, Inc.(“賣方”)訂立股份購買協議,據此,11736655 CANADA LTD.同意以加幣420萬元(相當於約319.2702萬美元)(其中加幣120萬元(相當於約91.2201萬美元)將受截至2022年12月31日止三個年度業績目標規限)的代價購買目前由賣方持有的BRI全部流通在外股份。
目標公司BRI為其現任總裁及創辦人David Kwok博士所創立的合同研究機構,於加拿大温哥華成立至今已逾20年。BRI從事為製藥及生物科技公司提供科學驅動的藥物發現及可提交研究性新藥╱新藥申請的研究。
作為合同研究機構,BRI為其客户羣提供多樣服務,包括但不限於測量候選藥物、代謝物及生物標記物的生物分析、體外藥物代謝╱吸收、分佈、代謝及排泄研究、體內藥物代謝和藥代動力學╱吸收、分佈、代謝及排泄研究、配方開發、 DS/DP穩定性及化學、製造和控制分析,以及抗癌藥物藥理評估。
公司認為,北美和中國的製藥行業外包預期將持續增長。收購事項能使公司運用現有優勢並擴大產能,以從製藥行業外包及對我們服務相關需求的預期增長中尋求機會。於收購事項完成後,公司將透過更多的科學家、設備及設施擴大其產能,以用於向公司的客户提供現有及全新的服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.